Bausch Health Companies Inc (BHC) Stock Price

BHCStock

$6.30+5.44%52W

Market Cap$2.36B

P/E15.13x

PEG Ratio0.01

Div yield—

Beta0.65

BHC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)3.15%

Price vs S&P 500 (4W)13.95%

PEG Ratio0.01

VGM Score71.59

P/E Ratio (Annual)15.13x

P/CF (Annual)1.70x

Book Value / Share (Quarterly)$1.51

P/TBV (Annual)86.50x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)8.11%

Cash Flow / Share (Quarterly)$3.73

Price vs S&P 500 (YTD)-18.33%

Gross Margin (TTM)71.82%

Net Profit Margin (TTM)-10.12%

EPS (TTM)$-2.96

10-Day Avg Trading Volume0.47M

EPS Excl Extra (TTM)$-2.96

Revenue Growth (5Y)5.04%

EPS (Annual)$0.42

ROI (Annual)-2.29%

Gross Margin (Annual)70.65%

Net Profit Margin (5Y Avg)-3.94%

Cash / Share (Quarterly)$4.88

P/E Basic Excl Extra (TTM)13.34x

Revenue Growth QoQ (YoY)12.73%

P/E Normalized (Annual)15.13x

ROA (Last FY)0.60%

Revenue Growth TTM (YoY)10.09%

EBITD / Share (TTM)$4.87

ROE (5Y Avg)-91.99%

Operating Margin (TTM)8.00%

Cash Flow / Share (Annual)$2.68

P/B Ratio4.44x

P/B Ratio (Quarterly)12.40x

Net Income / Employee (Annual)$7,700

EV / Revenue (TTM)1.97x

Net Interest Coverage (TTM)1.23x

ROA (TTM)-4.29%

EPS Growth QoQ (YoY)72.02%

EV / EBITDA (TTM)11.70x

EPS Incl Extra (Annual)$0.42

Current Ratio (Annual)1.47x

Quick Ratio (Quarterly)0.90x

3-Month Avg Trading Volume0.63M

52-Week Price Return5.44%

EV / Free Cash Flow (Annual)21.48x

P/E Incl Extra (TTM)13.34x

Revenue / Employee (TTM)$534,600

Tangible BV / Share (Quarterly)$0.61

P/S Ratio (Annual)0.23x

Asset Turnover (Annual)0.39x

52-Week High$11.08

Operating Margin (5Y Avg)13.50%

EPS Excl Extra (Annual)$0.42

CapEx CAGR (5Y)5.66%

Tangible BV CAGR (5Y)-21.06%

26-Week Price Return13.05%

Quick Ratio (Annual)0.88x

13-Week Price Return30.22%

Total Debt / Equity (Annual)44.72x

Current Ratio (Quarterly)1.44x

Enterprise Value$21.33B

Revenue / Share Growth (5Y)3.90%

Asset Turnover (TTM)0.42x

Book Value / Share Growth (5Y)-38.57%

Revenue / Employee (Annual)$505,700

Inventory Turnover (Annual)1.87x

Pretax Margin (Annual)3.57%

Cash / Share (Annual)$3.53

3-Month Return Std Dev76.81%

Gross Margin (5Y Avg)71.01%

Net Income / Employee (TTM)$-54,100

EBITDA CAGR (5Y)5.64%

EBITDA Interim CAGR (5Y)84.61%

ROE (Last FY)-104.67%

Net Interest Coverage (Annual)0.54x

EPS Basic Excl Extra (Annual)$0.42

P/FCF (TTM)1.71x

Receivables Turnover (TTM)4.85x

EV / Free Cash Flow (TTM)15.31x

Total Debt / Equity (Quarterly)44.72x

EPS Incl Extra (TTM)$-2.96

Receivables Turnover (Annual)4.57x

ROI (TTM)-2.25%

P/S Ratio (TTM)0.22x

Pretax Margin (5Y Avg)-2.57%

Revenue / Share (Annual)$27.38

Tangible BV / Share (Annual)$0.12

Forward P/E1.30x

Free OCF CAGR (5Y)4.37%

Price vs S&P 500 (52W)-10.09%

P/E Ratio (TTM)13.34x

Year-to-Date Return-6.40%

5-Day Price Return3.24%

EPS Normalized (Annual)$0.42

ROA (5Y Avg)-1.17%

Net Profit Margin (Annual)1.53%

Month-to-Date Return7.60%

Cash Flow / Share (TTM)$1.20

EBITD / Share (Annual)$7.94

Operating Margin (Annual)19.24%

LT Debt / Equity (Annual)44.72x

P/CF (TTM)1.32x

ROI (5Y Avg)-4.82%

P/E Excl Extra (TTM)13.34x

LT Debt / Equity (Quarterly)44.72x

EPS Basic Excl Extra (TTM)$-2.96

P/TBV (Quarterly)23.70x

P/B Ratio (Annual)12.40x

Inventory Turnover (TTM)1.88x

Pretax Margin (TTM)-6.74%

Book Value / Share (Annual)$1.51

Price vs S&P 500 (13W)27.53%

Beta0.65x

P/FCF (Annual)2.39x

Revenue / Share (TTM)$28.70

ROE (TTM)-96.76%

52-Week Low$6.10

vGradeB

gGradeC

mGradeA

vgmGradeB

BHC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 29, 2026	$1.01	$1.26	+25.12%(+$0.25)
Q1 2026	Apr 29, 2026	$0.69	$0.78	+12.81%(+$0.09)
Q4 2025	Feb 18, 2026	$1.26	$1.10	-12.85%(-$0.16)
Q3 2025	Oct 29, 2025	$1.06	$1.16	+10.00%(+$0.11)
Q2 2025	Jul 30, 2025	$0.94	$0.91	-4.09%(-$0.04)

BHC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.44

2.38

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BHCBausch Health Companies Inc	B	C	A	0.2x	10.1%	71.8%	—	$6.30
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Bausch Health Companies Inc

Bausch Health Companies is a diversified global pharmaceutical and medical device company focused on specialty care markets including gastroenterology, hepatology, neurology, and dermatology. Revenue is driven by its portfolio of branded products across Bausch + Lomb (eye care, largest segment), Salix (gastroenterology), Solta Medical (aesthetics), and other diversified products.

BHC Next Earnings Report

Report dateOct 28, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$1.24

Revenue estimate$2.75B

Also reporting on Oct 28, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

BHC Insider Transactions

SellAug 19, 2026
LENAR AIMEE J
Officer
Shares: 36,827Value: $258,894

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

2.4

Sell

Consensus rating

52-Week Range

Low$6.10

High$11.08